Myriad Genetics, Inc. (0K3W.L)
USD 8.13
(0.12%)
USD 8.13
(0.12%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 312.9 Million USD | -11.33% |
| 2021 | 352.9 Million USD | -34.38% |
| 2020 | 537.8 Million USD | 13.51% |
| 2019 | 473.8 Million USD | 0.0% |
| 2018 | 473.8 Million USD | 126.48% |
| 2017 | 209.2 Million USD | -53.16% |
| 2016 | 446.6 Million USD | 237.31% |
| 2015 | 132.4 Million USD | 27.19% |
| 2014 | 104.1 Million USD | -0.68% |
| 2013 | 104.81 Million USD | 39.33% |
| 2012 | 75.22 Million USD | 36.84% |
| 2011 | 54.97 Million USD | 24.84% |
| 2010 | 44.03 Million USD | 21.42% |
| 2009 | 36.26 Million USD | 12.62% |
| 2008 | 32.2 Million USD | -56.3% |
| 2007 | 73.68 Million USD | 132.42% |
| 2006 | 31.7 Million USD | 18.2% |
| 2005 | 26.82 Million USD | 15.19% |
| 2004 | 23.28 Million USD | 54.41% |
| 2003 | 15.08 Million USD | -22.01% |
| 2002 | 19.33 Million USD | -32.2% |
| 2001 | 28.52 Million USD | -12.47% |
| 2000 | 32.58 Million USD | 13.66% |
| 1999 | 28.66 Million USD | 430.9% |
| 1998 | 5.4 Million USD | -45.45% |
| 1997 | 9.9 Million USD | 0.0% |
| 1996 | 9.9 Million USD | 5.32% |
| 1995 | 9.4 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 334.1 Million USD | 6.78% |
| 2023 Q3 | 465.7 Million USD | 3.03% |
| 2023 Q2 | 452 Million USD | 35.29% |
| 2022 Q4 | 312.9 Million USD | 5.92% |
| 2022 Q1 | 305.3 Million USD | -13.49% |
| 2022 Q3 | 295.4 Million USD | 12.4% |
| 2022 Q2 | 262.8 Million USD | -13.92% |
| 2022 FY | 312.9 Million USD | -11.33% |
| 2021 FY | 352.9 Million USD | -34.38% |
| 2021 Q2 | 457.9 Million USD | -0.82% |
| 2021 Q3 | 367.4 Million USD | -19.76% |
| 2021 Q4 | 352.9 Million USD | -3.95% |
| 2021 Q1 | 461.7 Million USD | -14.33% |
| 2020 Q1 | 479.5 Million USD | -4.29% |
| 2020 Q3 | 535.2 Million USD | 10.03% |
| 2020 Q2 | 486.4 Million USD | 1.44% |
| 2020 FY | 537.8 Million USD | 13.51% |
| 2020 Q4 | 538.9 Million USD | 0.69% |
| 2019 Q4 | 501 Million USD | -3.04% |
| 2019 Q2 | 473.8 Million USD | -0.38% |
| 2019 FY | 473.8 Million USD | 0.0% |
| 2019 Q1 | 475.6 Million USD | -3.43% |
| 2019 Q3 | 516.7 Million USD | 9.05% |
| 2018 FY | 473.8 Million USD | 126.48% |
| 2018 Q1 | 270.1 Million USD | -14.06% |
| 2018 Q2 | 209.2 Million USD | -22.55% |
| 2018 Q3 | 471.4 Million USD | 125.33% |
| 2018 Q4 | 492.5 Million USD | 4.48% |
| 2017 Q4 | 314.3 Million USD | -12.13% |
| 2017 FY | 209.2 Million USD | -53.16% |
| 2017 Q3 | 357.7 Million USD | -19.91% |
| 2017 Q2 | 446.6 Million USD | -14.1% |
| 2017 Q1 | 519.9 Million USD | -4.32% |
| 2016 Q2 | 132.4 Million USD | 35.1% |
| 2016 FY | 446.6 Million USD | 237.31% |
| 2016 Q4 | 543.4 Million USD | 1.46% |
| 2016 Q1 | 98 Million USD | -2.87% |
| 2016 Q3 | 535.6 Million USD | 304.53% |
| 2015 FY | 132.4 Million USD | 27.19% |
| 2015 Q3 | 99.9 Million USD | -4.03% |
| 2015 Q4 | 100.9 Million USD | 1.0% |
| 2015 Q2 | 104.1 Million USD | -5.49% |
| 2015 Q1 | 110.15 Million USD | 25.72% |
| 2014 Q1 | 94.18 Million USD | 16.69% |
| 2014 Q4 | 87.61 Million USD | -9.54% |
| 2014 Q2 | 104.81 Million USD | 11.29% |
| 2014 FY | 104.1 Million USD | -0.68% |
| 2014 Q3 | 96.85 Million USD | -7.59% |
| 2013 Q1 | 64.09 Million USD | 15.23% |
| 2013 Q4 | 80.71 Million USD | -11.68% |
| 2013 Q3 | 91.38 Million USD | 21.48% |
| 2013 Q2 | 75.22 Million USD | 17.36% |
| 2013 FY | 104.81 Million USD | 39.33% |
| 2012 FY | 75.22 Million USD | 36.84% |
| 2012 Q4 | 55.62 Million USD | -17.58% |
| 2012 Q1 | 47.06 Million USD | 5.77% |
| 2012 Q2 | 54.97 Million USD | 16.82% |
| 2012 Q3 | 67.49 Million USD | 22.77% |
| 2011 Q2 | 44.03 Million USD | 34.17% |
| 2011 FY | 54.97 Million USD | 24.84% |
| 2011 Q4 | 44.49 Million USD | 9.21% |
| 2011 Q3 | 40.74 Million USD | -7.48% |
| 2011 Q1 | 32.82 Million USD | 0.96% |
| 2010 Q3 | 39.73 Million USD | 9.55% |
| 2010 Q4 | 32.5 Million USD | -18.18% |
| 2010 FY | 44.03 Million USD | 21.42% |
| 2010 Q1 | 22.21 Million USD | -2.18% |
| 2010 Q2 | 36.26 Million USD | 63.24% |
| 2009 Q1 | 36.5 Million USD | -32.18% |
| 2009 Q4 | 22.71 Million USD | 8.18% |
| 2009 Q2 | 32.2 Million USD | -11.78% |
| 2009 FY | 36.26 Million USD | 12.62% |
| 2009 Q3 | 20.99 Million USD | -34.81% |
| 2008 Q2 | 73.68 Million USD | 95.66% |
| 2008 Q4 | 53.82 Million USD | -0.67% |
| 2008 FY | 32.2 Million USD | -56.3% |
| 2008 Q1 | 37.66 Million USD | 7.94% |
| 2008 Q3 | 54.18 Million USD | -26.47% |
| 2007 Q4 | 34.89 Million USD | 10.33% |
| 2007 Q1 | 22.96 Million USD | -13.27% |
| 2007 FY | 73.68 Million USD | 132.42% |
| 2007 Q2 | 31.7 Million USD | 38.08% |
| 2007 Q3 | 31.62 Million USD | -0.26% |
| 2006 Q4 | 26.47 Million USD | 15.36% |
| 2006 FY | 31.7 Million USD | 18.2% |
| 2006 Q3 | 22.94 Million USD | -14.45% |
| 2006 Q1 | 21.59 Million USD | -8.44% |
| 2006 Q2 | 26.82 Million USD | 24.22% |
| 2005 Q3 | 22.34 Million USD | -4.03% |
| 2005 FY | 26.82 Million USD | 15.19% |
| 2005 Q1 | 16.53 Million USD | -4.72% |
| 2005 Q2 | 23.28 Million USD | 40.79% |
| 2005 Q4 | 23.58 Million USD | 5.53% |
| 2004 Q4 | 17.35 Million USD | 25.24% |
| 2004 Q2 | 15.08 Million USD | 1.62% |
| 2004 FY | 23.28 Million USD | 54.41% |
| 2004 Q3 | 13.86 Million USD | -8.08% |
| 2004 Q1 | 14.84 Million USD | 15.13% |
| 2003 Q1 | 12.91 Million USD | -40.38% |
| 2003 Q4 | 12.89 Million USD | 5.57% |
| 2003 Q3 | 12.21 Million USD | -36.86% |
| 2003 Q2 | 19.33 Million USD | 49.68% |
| 2003 FY | 15.08 Million USD | -22.01% |
| 2002 FY | 19.33 Million USD | -32.2% |
| 2002 Q2 | 28.52 Million USD | 50.65% |
| 2002 Q3 | 16.08 Million USD | -43.6% |
| 2002 Q1 | 18.93 Million USD | -7.0% |
| 2002 Q4 | 21.66 Million USD | 34.72% |
| 2001 Q3 | 21.97 Million USD | -32.57% |
| 2001 Q1 | 23.01 Million USD | 6.04% |
| 2001 Q2 | 32.58 Million USD | 41.58% |
| 2001 Q4 | 20.35 Million USD | -7.35% |
| 2001 FY | 28.52 Million USD | -12.47% |
| 2000 Q3 | 24.02 Million USD | -16.18% |
| 2000 Q4 | 21.7 Million USD | -9.68% |
| 2000 Q2 | 28.66 Million USD | 26.76% |
| 2000 Q1 | 22.61 Million USD | 22.92% |
| 2000 FY | 32.58 Million USD | 13.66% |
| 1999 Q2 | 5.4 Million USD | -6.9% |
| 1999 Q4 | 18.4 Million USD | 28.67% |
| 1999 Q3 | 14.3 Million USD | 164.81% |
| 1999 FY | 28.66 Million USD | 430.9% |
| 1999 Q1 | 5.8 Million USD | -12.12% |
| 1998 Q3 | 7.8 Million USD | -21.21% |
| 1998 FY | 5.4 Million USD | -45.45% |
| 1998 Q4 | 6.6 Million USD | -15.38% |
| 1998 Q1 | 9.2 Million USD | -6.12% |
| 1998 Q2 | 9.9 Million USD | 7.61% |
| 1997 Q3 | 10 Million USD | 1.01% |
| 1997 FY | 9.9 Million USD | 0.0% |
| 1997 Q4 | 9.8 Million USD | -2.0% |
| 1997 Q1 | 8.7 Million USD | -9.38% |
| 1997 Q2 | 9.9 Million USD | 13.79% |
| 1996 Q2 | 9.4 Million USD | 1.08% |
| 1996 Q1 | 9.3 Million USD | 75.47% |
| 1996 FY | 9.9 Million USD | 5.32% |
| 1996 Q4 | 9.6 Million USD | -4.0% |
| 1996 Q3 | 10 Million USD | 6.38% |
| 1995 Q4 | 5.3 Million USD | 0.0% |
| 1995 FY | 9.4 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 49.857% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -148.138% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 49.345% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -18.194% |
| bluebird bio, Inc. | 424.62 Million USD | 26.311% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -355.068% |
| Imunon, Inc. | 8.53 Million USD | -3568.046% |
| Editas Medicine, Inc. | 150.05 Million USD | -108.522% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 98.479% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 91.074% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 69.305% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 35.81% |
| Verastem, Inc. | 71.18 Million USD | -339.559% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.546% |
| Waters Corporation | 3.47 Billion USD | 91.0% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.397% |
| Biogen Inc. | 12.04 Billion USD | 97.402% |
| Nektar Therapeutics | 267.04 Million USD | -17.171% |
| Perrigo Company plc | 6.04 Billion USD | 94.821% |
| Dynavax Technologies Corporation | 375.02 Million USD | 16.565% |
| Illumina, Inc. | 4.36 Billion USD | 92.833% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -789.499% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -59.857% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -21.998% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -739.054% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 83.445% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -279.581% |
| Evolus, Inc. | 209.68 Million USD | -49.222% |
| Adicet Bio, Inc. | 37.12 Million USD | -742.942% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -677.855% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 95.597% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 52.648% |
| FibroGen, Inc. | 585.72 Million USD | 46.579% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 93.638% |
| OPKO Health, Inc. | 622.47 Million USD | 49.733% |
| Homology Medicines, Inc. | 118.53 Million USD | -163.977% |
| Geron Corporation | 146.12 Million USD | -114.129% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 92.275% |
| Exelixis, Inc. | 678.44 Million USD | 53.88% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1458.966% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -2396.41% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -24.757% |
| Zoetis Inc. | 9.29 Billion USD | 96.634% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 21.235% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -536.286% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 93.924% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -545.887% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 87.981% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 86.991% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -172.532% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 81.03% |
| Blueprint Medicines Corporation | 918.64 Million USD | 65.939% |
| Insmed Incorporated | 1.66 Billion USD | 81.171% |
| TG Therapeutics, Inc. | 169.08 Million USD | -85.055% |
| Incyte Corporation | 1.59 Billion USD | 80.349% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 73.608% |